Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy
AACR Virtual Annual Meeting 2020Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or chemotherapy (Abstract CT086).
Related Videos
Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib
Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced ...
Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed prelimina...
Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel
Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with hig...
Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations
Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number o...
Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses an exploratory analysis seeking to identify tumor-based molecular biomarkers that may be associated with ...
